Goldpharmacysp. z o.o.

Dispensing chemist in specialised stores

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-01-23
Share capital
50,000.00 PLN
Registered address
ul. Jakuba Przyłuskiego 5, 05-080 Izabelin C, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2022 – the filing deadline has passed. 4 of 4 financial statements were filed late (the longest delay 838 days for 2020).

  • 2022not filed
  • 202131/01/2024
  • 202031/01/2024
  • 201906/11/2020
  • 201806/11/2020
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2021.

Top 83%
Division · Retail trade7,326 / 13,246
Top 55%
Voivodeship · Mazowieckie47,001 / 142,035
Top 33%
Country · Poland172,299 / 495,866
Top 35%

Results vs industry

Revenue
This companyUSD 509.64kMedianUSD 1.92mAverageUSD 5.20m
Net profit
This companyUSD 35.07kMedianUSD 20.70kAverageUSD 86.94k
Operating costs
This companyUSD 468.96kMedianUSD 1.88mAverageUSD 5.04m
Assets
This companyUSD 170.41kMedianUSD 543.65kAverageUSD 1.76m

Authorized Representatives

Irena Stypułkowska – Attorney-in-fact (sole)
Krzysztof Stypułkowski – Management Board Member

Manner of representation

Each member of the management board independently.

Ownership

OwnerSharesShare valueStake
Joanna Aneta Kuneckaage 46
5$6,753.1150%
Krzysztof Stypułkowskiage 38
5$6,753.1150%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2015-02-24.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

4 public aid cases recorded, with a total value of $7,683.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
–
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
–
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
–

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
MagmaxS.A.
DR Poradasp. z o.o.
Novopharm - Millersp. j.
MaglowS.A.
Farmacja Im. O. Klimuszkisp. z o.o.
Macromedicasp. z o.o.
IMA-MEDsp. z o.o.
Nasza Zielarniasp. z o.o.
Nukloversp. z o.o.
Massmedsp. z o.o.

FAQ

Last updated: 2026-10-20